T-Cell Response and Antibody Production Induced by the COVID-19 Booster Vaccine in Japanese Chronic Kidney Disease Patients Treated with Hemodialysis
Humoral and cellular responses are critical in understanding immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Here, we evaluated these responses in hemodialysis (HD) patients after the booster vaccination. SARS-CoV-2 immunoglobulin (IgG) levels, neutralizing antibody titers, and the T-SPOT®.COVID test (T-SPOT) were measured prior to, three weeks after, and three months after the booster administration. The HD group had significantly higher SARS-CoV-2 IgG levels and neutralizing antibody titers against the original strain at three weeks and three months after the booster vaccination compared to the control group, albeit the HD group had lower SARS-CoV-2 IgG levels and neutralizing antibody titers before the booster administration. Moreover, the HD group had significantly higher T-SPOT levels at all three time points compared to the control group. The HD group also had significantly higher local and systemic adverse reaction rates than the control group. By booster vaccination, HD patients could acquire more effective SARS-CoV-2-specific humoral and cellular immunity than the control group.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Vaccines - 11(2023), 3 vom: 14. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yoshifuji, Ayumi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adverse reactions |
|---|
| Anmerkungen: |
Date Revised 01.04.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/vaccines11030653 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM354971778 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM354971778 | ||
| 003 | DE-627 | ||
| 005 | 20231226063351.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/vaccines11030653 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1183.xml |
| 035 | |a (DE-627)NLM354971778 | ||
| 035 | |a (NLM)36992238 | ||
| 035 | |a (PII)653 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yoshifuji, Ayumi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a T-Cell Response and Antibody Production Induced by the COVID-19 Booster Vaccine in Japanese Chronic Kidney Disease Patients Treated with Hemodialysis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 01.04.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Humoral and cellular responses are critical in understanding immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Here, we evaluated these responses in hemodialysis (HD) patients after the booster vaccination. SARS-CoV-2 immunoglobulin (IgG) levels, neutralizing antibody titers, and the T-SPOT®.COVID test (T-SPOT) were measured prior to, three weeks after, and three months after the booster administration. The HD group had significantly higher SARS-CoV-2 IgG levels and neutralizing antibody titers against the original strain at three weeks and three months after the booster vaccination compared to the control group, albeit the HD group had lower SARS-CoV-2 IgG levels and neutralizing antibody titers before the booster administration. Moreover, the HD group had significantly higher T-SPOT levels at all three time points compared to the control group. The HD group also had significantly higher local and systemic adverse reaction rates than the control group. By booster vaccination, HD patients could acquire more effective SARS-CoV-2-specific humoral and cellular immunity than the control group | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a adverse reactions | |
| 650 | 4 | |a cellular immunity | |
| 650 | 4 | |a hemodialysis | |
| 650 | 4 | |a humoral immunity | |
| 650 | 4 | |a vaccination | |
| 650 | 4 | |a vaccine | |
| 700 | 1 | |a Toda, Masataro |e verfasserin |4 aut | |
| 700 | 1 | |a Ryuzaki, Munekazu |e verfasserin |4 aut | |
| 700 | 1 | |a Oyama, Emi |e verfasserin |4 aut | |
| 700 | 1 | |a Kikuchi, Kan |e verfasserin |4 aut | |
| 700 | 1 | |a Kawai, Toru |e verfasserin |4 aut | |
| 700 | 1 | |a Sakai, Ken |e verfasserin |4 aut | |
| 700 | 1 | |a Koinuma, Masayoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Katayama, Kazuhiko |e verfasserin |4 aut | |
| 700 | 1 | |a Yokoyama, Takashi |e verfasserin |4 aut | |
| 700 | 1 | |a Uehara, Yuki |e verfasserin |4 aut | |
| 700 | 1 | |a Ohmagari, Norio |e verfasserin |4 aut | |
| 700 | 1 | |a Kanno, Yoshihiko |e verfasserin |4 aut | |
| 700 | 1 | |a Kon, Hirofumi |e verfasserin |4 aut | |
| 700 | 1 | |a Shinoda, Toshio |e verfasserin |4 aut | |
| 700 | 1 | |a Takano, Yaoko |e verfasserin |4 aut | |
| 700 | 1 | |a Tanaka, Junko |e verfasserin |4 aut | |
| 700 | 1 | |a Hora, Kazuhiko |e verfasserin |4 aut | |
| 700 | 1 | |a Nakazawa, Yasushi |e verfasserin |4 aut | |
| 700 | 1 | |a Hasegawa, Naoki |e verfasserin |4 aut | |
| 700 | 1 | |a Hanafusa, Norio |e verfasserin |4 aut | |
| 700 | 1 | |a Hinoshita, Fumihiko |e verfasserin |4 aut | |
| 700 | 1 | |a Morikane, Keita |e verfasserin |4 aut | |
| 700 | 1 | |a Wakino, Shu |e verfasserin |4 aut | |
| 700 | 1 | |a Nakamoto, Hidetomo |e verfasserin |4 aut | |
| 700 | 1 | |a Takemoto, Yoshiaki |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Vaccines |d 2012 |g 11(2023), 3 vom: 14. März |w (DE-627)NLM239212347 |x 2076-393X |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2023 |g number:3 |g day:14 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/vaccines11030653 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2023 |e 3 |b 14 |c 03 | ||